“The apprehension with working with non IID shown ingredients is justified as it really is difficult to evaluate if FDA would find the ‘novel excipient’ Harmless to be used inside a drug product as there's no described method for evaluation and acceptance of excipients. The FDA advice on ‘Nonclinical https://proleviate.com/